AMENDMENTS

In the claims:

Please amend the claims as indicated below:

28. (Previously Amended) The vaccine composition of claim 30, wherein said antigen is an influenza antigen.

30. (Currently Amended) A vaccine composition comprising at least one non-nucleic acid antigen and an adjuvanting amount of 3-β-(N-(N'-N'-dimethylaminoethane)carbamoyl) cholesterol.

31. (Canceled) The vaccine composition of claim 30, wherein said amphipathic adjuvant compound is 3E-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol.

32. (Canceled) The vaccine composition of claim 30, wherein said amphipathic adjuvant compound is 3β-(N-(polyethylenamine)carbamoyl) cholesterol.

33. (Previously Amended) The vaccine composition of claim 30, further comprising a neutral lipid.

34. (Previously Amended) The vaccine composition of claim 33, wherein the ratio of said neutral lipid to said amphipathic adjuvant compound is greater than 1:4.

35. (Previously Added) The vaccine composition of claim 33, wherein said neutral lipid is dioleoylphosphatidylethanolamine or dioleoylphosphatidylcholine.

36. (Currently Amended) The vaccine composition of claim 30, wherein said 3-β-(N-(N'-N'-dimethylaminoethane)carbamoyl) cholesterol is dispersed in an aqueous environment in the form of liposomes.

37. (Previously Amended) The vaccine composition of claim 30, wherein said 3-β-(N-(N-N'-dimethylaminoethane)carbamoyl) cholesterol takes the form of liposomes including at least one antigen.

38. – 60. (Canceled)

61. (Canceled) The vaccine composition of claim 50, wherein said amphipathic adjuvant compound is dispersed in an aqueous environment in the form of liposomes.

62. (Previously Amended) A method of inducing an immune response in a mammal, comprising administering the vaccine composition of claim 30, to a mammal.

63. (Previously Added) The method of claim 62, wherein said immune response is a humoral immune response.

64. (Previously Added) The method of claim 62, wherein said immune response is a cytotoxic T cell response.

65. (Previously Added) The method of claim 62, wherein said immune response is a TH_1-type immune response.

66. (Previously Added) The method of claim 62, wherein said antigen is an influenza virus haemagglutinin.

67. (Previously Added) The method of claim 62, wherein said vaccine composition is administered by the subcutaneous route.

68. (Previously Added) The method of claim 62, wherein said vaccine composition is administered by the mucosal route.

69. (Previously Added) The method of claim 62, wherein said vaccine composition is administered by the intranasal route.

75. (Previously Amended) A method of inducing an immune response in a mammal, comprising administering an immunogenic amount of the vaccine composition of claim 30 to a mammal.

76. (Previously Added) The method of claim 75, wherein the antigen is an influenza virus haemagglutinin.

77. (Previously Added) The method of claim 75, wherein said immune response is a humoral immune response.

78. (Previously Added) The method of claim 75, wherein said immune response is a cytotoxic T cell response.

79. (Previously Added) The method of claim 75, wherein said immune response is a TH_1-type immune response.

80. (Previously Amended) The method of claim 75, wherein said composition is administered by the subcutaneous route.

81. (Previously Amended) The method of claim 75, wherein said composition is administered by the mucosal route.

82. (Previously Amended) The method of claim 75, wherein said composition is administered by the intranasal route.

83. (Canceled) The method of claim 75, wherein said lipophilic group is a cholesterol derivative.

84. (Canceled) The method of claim 83, wherein said amphipathic adjuvant compound is selected from the group consisting of cholesteryl-3-β-carboxamidoethylenetrimethylammonium iodide, cholesteryl-3-β-carboxamidoethylenamine, cholesteryl-3β-oxysuccinamidoethylenetrimethylammonium iodide, 3β-(N-(N', N'-dimethylaminoethane)carbamoyl) cholesterol, and 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

85. (Canceled) The method of claim 84, wherein said amphipathic adjuvant compound is 3β-(N-(N',N'-dimethylaminoethane)carbamoyl) cholesterol.

86. (Canceled) The method of claim 84, wherein said amphipathic adjuvant compound is 3β-(N-(polyethylemanime carbamoyl) cholesterol.

87. (Previously Added) The method of claim 65, wherein said antigen is an influenza virus haemagglutinin.

88. (Previously Added) The method of claim 79, wherein said antigen is an influenza virus haemagglutinin.

89. (Canceled) The vaccine composition according to claim 30 wherein the antigen is a non-nucleic acid antigen.

90. (Previously added) The vaccine composition according to claim 30 wherein the antigen is a proteinaceous acid antigen.

91. (Previously added) The vaccine composition of claim 89 wherein the ratio of said neutral lipid to said amphipathic adjuvant compound is greater than 1:4.

92. (Previously added) The vaccine composition of claim 90, wherein the ratio of said neutral lipid to said amphipathic adjuvant compound is greater than 1:4.

93. (Previously added) A method of inducing an immune response in a mammal comprising administering the vaccine composition of claim 89 to a mammal.

94. (Previously added) A method of inducing an immune response in a mammal comprising administering the vaccine composition of claim 90 to a mammal.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
(312)913-0001